Vicadrostat is under clinical development by Boehringer Ingelheim International and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure).
FDA sends warning letter to defibrillator battery manufacturer
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration